Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

被引:1
|
作者
Carvalhaes, Cecilia G. [1 ]
Huband, Michael D. [1 ]
Reinhart, Harald H. [2 ]
Flamm, Robert K. [1 ]
Sader, Helio S. [1 ]
机构
[1] JMI Labs, North Liberty, IA 52317 USA
[2] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
关键词
Staphylococcus aureus; Streptococcus pneumoniae; aminomethylcycline; community-acquired pneumonia; skin and soft tissue infections; tetracyclines; RESISTANCE; EPIDEMIOLOGY;
D O I
10.1128/AAC.02262-18
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gramnegative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against Staphylococcus aureus (n = 689; MIC50/90, 0.12/0.25 mg/liter), including methicillin-resistant Staphylococcus aureus (MRSA; n = 299; MIC50/90, 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against Streptococcus pneumoniae (highest MIC, 0.25 mg/liter), beta-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and Enterococcus spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of S. pneumoniae isolates were penicillin resistant (penicillin MIC, >2 mg/liter) and 10.7% of enterococci (21.2% among E. faecium isolates) were vancomycin resistant. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1 mg/liter) regardless of beta-lactamase production and was active against Moraxella catarrhalis (MIC50/90, <= 0.12/0.25 mg/liter). Against Enterobacteriaceae, omadacycline was most active against Escherichia coli (MIC50/90, 1/2 mg/liter), Klebsiella oxytoca (MIC50/90, 1/4 mg/liter), and Enterobacter cloacae (MIC50/90, 2/4 mg/liter). Omadacycline had potent in vitro activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant S. pneumoniae (PRSPN), and extended-spectrum beta-lactamase-producing E. coli. The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016)
    Gales, Ana C.
    Seifert, Harald
    Gur, Deniz
    Castanheira, Mariana
    Jones, Ronald N.
    Sader, Helio S.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 : S34 - S46
  • [12] BMS284756 potency and spectrum tested against over 10000 bacterial blood stream infection isolates from the Sentry Antimicrobial Surveillance Program (2000)
    Fix, AM
    Pfaller, MA
    Biedenbach, DJ
    Beach, ML
    Jones, RN
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 : 26 - 27
  • [13] Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
    Fluit, AC
    Jones, ME
    Schmitz, FJ
    Acar, J
    Gupta, R
    Verhoef, J
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) : 454 - 460
  • [14] Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Jones, Ronald N.
    Sader, Helio S.
    Fritsche, Thomas R.
    Pottumarthy, Sudha
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 57 (01) : 109 - 116
  • [15] Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program
    Deshpande, L. M.
    Castanheira, M.
    Flamm, R. K.
    Mendes, R. E.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (09) : 2314 - 2322
  • [16] Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997
    Fluit, AC
    Jones, ME
    Schmitz, FJ
    Acar, J
    Gupta, R
    Verhoef, J
    ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 2000, 77 (02): : 147 - 152
  • [17] Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997
    Ad C. Fluit
    Mark E. Jones
    Franz-Josef Schmitz
    Jacques Acar
    Renu Gupta
    Jan Verhoef
    Antonie van Leeuwenhoek, 2000, 77 : 147 - 152
  • [18] Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003)
    Sader, HS
    Fritsche, TR
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (03) : 265 - 273
  • [19] Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: Report from the SENTRY Antimicrobial Surveillance Program
    Gales, AC
    Andrade, SS
    Sader, HS
    Jones, RN
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (04) : 323 - 328
  • [20] Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals - China, 2022
    Guo, Yan
    Ding, Li
    Yang, Yang
    Han, Renru
    Yin, Dandan
    Wu, Shi
    Zhu, Demei
    Hu, Fupin
    CHINA CDC WEEKLY, 2023, 5 (52): : 1155 - +